Drug intelligence / Profile preview

Lumacan

Development stage: Unknown
Lead developer: Salix Pharmaceuticals
Modality: Small Molecules
Administration: Rectal

Overview

**Lumacan** is a novel diagnostic agent developed for improving colorectal cancer screening by aiding in the detection of precancerous and cancerous lesions in the colon during endoscopy. It was licensed by Salix Pharmaceuticals from Photocure ASA, fitting into Salix's portfolio of gastrointestinal-focused therapeutics and diagnostics.[1][12][15]

Brand names: Lumacan

Beyond the preview

Go deeper on Lumacan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumacan.

Explore the full profile